Dr. Sachiko Kuno
Sachiko Kuno, Ph.D.
President & CEO

Dr. Sachiko Kuno studied biochemistry and biochemical engineering as one of a few Japanese female scientists. She obtained her Ph.D. in biochemical engineering from Kyoto University, Japan and has conducted post-doctoral research at the Technical University of Munich, Germany. In the mid-80s, Dr. Kuno joined her research partner, Dr. Ryuji Ueno, and established R-Tech Ueno Ltd. in Japan to commercialize prostones, a class of functional fatty acids whose therapeutic potential was first identified by Dr. Ueno. Leading teams of talented scientists, Drs. Ueno and Kuno unlocked the therapeutic potential of prostones, leading to more than 900 patents and patent applications successful launch of Rescula® eye drops, the first bioactive lipid ever used to treat glaucoma, in Japan.

Dr. Sachiko Kuno studied biochemistry and biochemical engineering as one of a few Japanese female scientists. She obtained her Ph.D. in biochemical engineering from Kyoto University, Japan and has conducted post-doctoral research at the Technical University of Munich, Germany. In the mid-80s, Dr. Kuno joined her research partner, Dr. Ryuji Ueno, and established R-Tech Ueno Ltd. in Japan to commercialize prostones, a class of functional fatty acids whose therapeutic potential was first identified by Dr. Ueno. Leading teams of talented scientists, Drs. Ueno and Kuno unlocked the therapeutic potential of prostones, leading to more than 900 patents and patent applications successful launch of Rescula® eye drops, the first bioactive lipid ever used to treat glaucoma, in Japan.

Leveraging R-Tech’s success in Japan, the two moved to Bethesda, MD and established Sucampo Group, an affiliation of companies in the Americas, Asia and Europe. Dr. Kuno was Sucampo Group’s founding CEO and Chair of the Board, until she stepped down in 2012. During her time at Sucampo, Dr. Kuno conducted research and development, the operation of the company, and the successful launch of the Drs.’ Second product AMITIZA® for the treatment of chronic idiopathic constipation in adults, irritable bowel syndrome with constipation and opioid-induced constipation in adults. Sucampo, which acquired R-Tech Ueno in 2015, is listed and traded on NASDAQ. In 2012, she co-founded VLP Therapeutics, LLC to combat 21st century global public health problems through revolutionary i-αVLP Technology.

Dr. Kuno currently serves as the President and CEO of S&R Foundation in Washington, D.C., a 501(c)(3) non-profit organization she co-founded in 2000 to support talented individuals with high aspirations and great potential in the arts, sciences and social entrepreneurship, especially those who are furthering international cultural collaboration.

In 2016, Dr. Kuno co-founded WE Capital, a female-led investment fund in Washington, D.C. An impact investment group, WE Capital invests in female leadership while promoting social impact and financial returns. She is also a founding member of the Greater Washington Partnership, a group of civic-minded business leaders committed to improving the greater Washington region.

Dr. Kuno is the co-founder and visionary creative behind Halcyon, launched in 2017, and its mission to catalyze and nurture emerging creatives striving for a better world. Driven by Dr. Kuno’s vision, Halcyon’s family of innovative programs, including the acclaimed Halcyon Incubator, is growing rapidly to include Halcyon Stage, a pioneering creatives series of performances and conversations, Halcyon Arts Lab, a residency based studio arts program, and Halcyon Dialogue, a series of high-level discussions among global experts focusing on major topics including implications of robots for global society and social impact-based sciences.

She currently serves on the Board of Trustees for Johns Hopkins Medicine, on the Board of Directors for The Maureen and Mike Mansfield Foundation, and on the Advisory Board of THIS for Diplomats at Meridian International Center. Dr. Kuno has received several awards over the years, including the Ernst and Young Entrepreneur of the Year Award for the Greater Washington Area in the Life Sciences Category (2007), and recognition as one of the 25 “Women Who Mean Business” by The Washington Business Journal (2009). She has also been named in Forbes Magazine’s Top 50 America’s Richest Self Made Women (2015) and the World’s 100 Most Powerful Women by Forbes Japan (2015). Most recently, Dr. Kuno was awarded Stateswoman of the Year 2016 by the Harvard Business School of Japan and received the AVON Awards to Women 2016.

Current Positions

  • Co-Founder & Managing Member, S&R Technology Holdings, LLC, Bethesda, Maryland
  • Co-Founder & Board of Directors, RUSK Intellectual Reserve AG, Zug, Switzerland
  • Co-Founder, President & CEO, S&R Foundation, Washington, D.C.
  • Co-Founder, WE Capital, Washington, D.C. 
  • Co-Founder, & Founding Board Member, Halcyon, Washington, D.C. 
  • Founding Member, Greater Washington Partnership
  • Specially appointed professor, Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University
  • Board of Trustees, Johns Hopkins Medicine, Baltimore, Maryland
  • Board of Trustees, Federal City Council
  • Board of Directors, The Maureen and Mike Mansfield Foundation, Washington, D.C.
  • Advisory Board Member, THIS for Diplomats at Meridian International Center, Washington, D.C.
  • Advisory Board Member, naisA Global
Ryuji Ueno, M.D., Ph.D., Ph.D.
Ryuji Ueno, M.D., Ph.D., Ph.D.
Honorary Chair, S&R Foundation

Dr. Ryuji Ueno, M.D., Ph.D. and Ph.D. is an internationally recognized scientist, innovator, entrepreneur, and philanthropist. Trained and certified as a Medical Doctor at Keio University School of Medicine in Japan, Dr. Ueno spent his academic career in the fields of pharmacology, physiology, and biochemistry at Columbia University, Kyoto University, Osaka University, and Stanford University. He has authored more than 100 articles in notable scientific journals. He is also passionate about classical music and is Founder and Executive Producer of the Ryuji Ueno Foundation.

Dr. Ryuji Ueno, M.D., Ph.D. and Ph.D. is an internationally recognized scientist, innovator, entrepreneur, and philanthropist. Trained and certified as a Medical Doctor at Keio University School of Medicine in Japan, Dr. Ueno spent his academic career in the fields of pharmacology, physiology, and biochemistry at Columbia University, Kyoto University, Osaka University, and Stanford University. He has authored more than 100 articles in notable scientific journals. He is also passionate about classical music and is Founder and Executive Producer of the Ryuji Ueno Foundation.

In the 1980s, Dr. Ueno first discovered the tremendous therapeutic potential of prostones, a class of functional fatty acids. After 10 years of biomedical research, he founded R-Tech Ueno, Ltd., a biopharmaceutical company that developed Rescula® (unoprostone), an anti-glaucoma medicine that has been used by more than 500,000 patients in 45 countries. In 1996, Dr. Ueno moved to the United States and established Sucampo Pharmaceuticals (SCMP, Nasdaq), which successfully developed a second medicine, AMITIZA® (lubiprostone), to treat various gastrointestinal conditions.

Dr. Ueno has received numerous awards and recognitions over the years, including Nikkei BP Publications’ Japan Innovator of the Year Award (2006), the Ernst & Young Entrepreneur of the Year Award for the Greater Washington Area in the Life Sciences Category (2006), honorary membership in the American Gastroenterological Association (2008), and the Foundation Fighting Blindness Visionary Award (2014).

In 2015, Dr. Ueno founded the Ryuji Ueno Foundation and serves as its Executive Producer. Through the foundation, Dr. Ueno produces more than 14 performances a year inviting world-renowned artists from around the globe. He also began the Potomac Music Lab Project, an incubator for classical music where world-class musicians can experiment with their craft. The Project includes The 6821 Quintet (6821 represents the distance in miles between Washington, DC, and Tokyo). This Quintet includes internationally renowned musicians, such as Mayu Kishima, the grand prize winner of the Shanghai Isaac Stern International Violin Competition (2016) and Tim Park, Grand Prize winner of the S&R Washington Award (2013). The Quintet performed its world debut at the National Cherry Blossom Festival in 2016. Dr.Ueno has also created a leadership program for international music students to learn what it means to be a professional performing artist in the United States. 

Dr. Ueno previously served as president of  the Evermay Chamber Orchestra, which joined The Washington Ballet to present live performances of “Swan Lake” at the Kennedy Center Eisenhower Theatre in April 2015.  He has also served as board member for The Washington Ballet (2014 -2015) and committee chair for the S&R Washington Award (2000 – 2015). He currently is a board member of The New Orchestra of Washington and sits on their program committee. He is also the Sponsor and Chief Lecturer of The Liechtenstein Academy of Music Washington, DC Semester.

Dr. Ueno routinely offers private coaching for pianists, violinists, violists, singers, guitarists, composers, and conductors, assisting numerous top tier artists from around the world.  He also coaches trio, quartets, quintets, and chamber orchestras. Dr. Ueno is passionate about classical music and is a collector of musical instruments. He is a major supporter of music in the greater Washington, DC, area and is himself a dedicated amateur flutist.  For his continued dedication and support of the arts, he has received the Mayor’s Art Award for Visionary Leadership at the 30th Annual Mayor’s Arts Award (2015) and the Business Philanthropist of the Year Award from the Washington Business Journal (2015).